Are There Legal Hallucinogens That Provide A Psychedelic Trip?
Last reviewed and updated: June 18, 2026.
Key Takeaways
| Most accessible (U.S.) | Ketamine — legal in all 50 states; Spravato FDA-approved for TRD; IV ketamine widely available off-label |
| Psilocybin (2025) | Oregon + Colorado regulated programs; clinical trials; Australia prescription-approved for TRD; still Schedule I federally |
| MDMA (2025) | FDA rejected MAPS PTSD application in 2024 — still Schedule I; additional Phase 3 trials underway; approval ~2028–2029 at earliest |
| Ibogaine (2025) | Schedule I in U.S. but legal in Mexico + some EU countries; Stanford 2023 veterans study generated congressional interest |
| Ayahuasca (U.S.) | Legal under religious freedom for federally recognized churches (UDV, Santo Daime); otherwise Schedule I; unregulated retreat industry carries safety risks |
The word hallucinogens is on everyone’s lips these days — but the question of their legal status still remains unknown. Are there legal hallucinogens that serve as positive mental health treatment and provide a psychedelic trip? We divulge.
RELATED: Can You Smoke Shrooms?
Psilocybin’s A Legal Hallucinogen In Some States
Best known as magic mushrooms (or ‘shrooms), psilocybin is one of the most common hallucinogens today. With a plethora of successful studies and many more underway, psilocybin has proven its incredible effect on those dealing with anxiety, PTSD, eating disorders, and treatment-resistant depression.
This is the main reason why organizations like the Multidisciplinary Association for Psychedelic Studies and John Hopkins Center for Psychedelics and Consciousness have been pursuing ways to conduct more randomized, large-scale trials in order to promote their efficacy.
Its legal status differs on the federal and state levels. Federally, it’s classified as a Schedule I substance under the Controlled Substances Act. This means that it has a “high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.”
Still, that doesn’t prevent the states (or cities, even) to change their view on psilocybin. In 2019, Denver, Colorado became the first city to decriminalize psilocybin, and later in the year, cities of Oakland and Santa Cruz, California followed suit. Washington D.C. did the same in November 2020, followed by Somerville in January 2021 and Cambridge Massachusetts in February 2021.
With powerful properties and therapeutic results, more cities may follow suit by decriminalizing these psychedelics.
RELATED: Legal Psychedelics: The U.S. Cities Where Psilocybin, LSD And Others Are Decriminalized
Ketamine As A Legal Hallucinogen Is Tricky
Mostly known in the medical and veterinarian world as a powerful and potent anesthetic, ketamine is legally classified as a Schedule III substance under the Controlled Substances Act. This means that it currently has accepted medical uses for short-term sedation and anesthesia.
In 2019, the FDA’s approval of a specific type of ketamine — Spravato, a nasal spray — allows for treatment-resistant depression at a doctor’s office or clinic.
On the state level, in addition to the nasal spray treatment, ketamine clinics nationwide also provide ketamine IV infusions. They aren’t regulated or approved by the FDA, but they are also not specifically prohibited — meaning they aren’t deemed illegal.
The biggest risk is with administering ketamine, since there is no proper regulation or approval. With no control over the source of ketamine or the dosage, this may present a danger to patients.
RELATED: What Does An MDMA Hangover Feel Like?
MDMA Therapy Is Gaining Traction
Another interesting hallucinogen, MDMA, also known as ecstasy, has a bit of a party-drug reputation. It is a Schedule I drug under the Controlled Substances Act, but certain organizations like MAPS have received FDA approval to conduct trials. Currently, they are in Phase III trials of MDMA-assisted therapy for PTSD, with an agreement on special protocol assessment.
The goal is to turn MDMA-assisted therapy for PTSD into an FDA-approved prescription treatment. There is an expectation that these trails will be complete in 2022, meaning the FDA could approve the treatment by 2023.
Ibogaine’s Effectiveness Continues To Shine
Another psychedelic classified as a Schedule I substance, ibogaine is also illegal on the federal level. Still, with many studies underway, it’s hard to imagine ibogaine not joining a list of legal hallucinogens at some point.
As a psychedelic that naturally occurs in the West African shrub iboga, ibogaine therapy has shown success for those struggling with addiction. These people often seek international clinics or underground providers to receive ibogaine treatment, since approval in the U.S. has yet to exist.
The Global Ibogaine Therapy Alliance supports the therapeutic uses of iboga through “sustainability initiatives, scientific research, education, and advocacy.” The group could provide a turning point to make this a legal hallucinogen.
RELATED: Why California Wasn’t Ready For The Magic: A Breakdown Of Senate Bill 519
Ayahuasca Is Legal… But With A Caveat
A famous South-American hallucinogenic drink, ayahuasca has many powerful and spiritual characteristics. These make it an important part of almost every shamanic ritual for thousands of years. Its cleansing properties help alleviate bad spirits and toxins — but there are ayahuasca dangers to be familiar with.
Its legal status once again classifies it as a Schedule I controlled substance. This deems it as high risk for abuse, with no current medical use in treatment in the United States. It contains a chemical called N,N- dimethyltryptamine, or DMT, and is therefore illegal to import, possess, sell, distribute, or consume.
A 2006 Supreme Court declaration allows members of a New Mexico church to legally use ayahuasca as a sacramental right. Santo Daime and União do Vegetal (UDV) are Brazilian “ayahuasca churches” with branches in the U.S. Each church use the psychedelic in spiritual sessions.
Some areas in the U.S. — such as Oakland, CA, Washington D.C., Santa Cruz, CA, Denver, CO, and Ann Arbor, MI — have decriminalized psilocybin and other natural psychedelics. This means that both possession and use can no longer lead to jail time. So, in terms of becoming a legal hallucinogen, it’s inching closer.
LSD Has An Uphill Battle
LSD is not a legal hallucinogen, as it falls under Schedule I of the Controlled Substances Act — with no current decriminalization of any sort. Although one of the earliest psychedelics with research, a ban of LSD began in the 1970s. It wasn’t until more recently that new trials and studies began taking place.
Most studies took place in the 1960s. But, more recently, there was the first completed double-blind, placebo-controlled study of the therapeutic use of LSD in human beings in four decades. The trends show positive signs in the reduction of anxiety. This is a great push towards more studies and, potentially, approval in human trials.
RELATED: What Causes Visuals In Psychedelic Trips?
Some Legal Hallucinogens Are Causing A Stir, But It’s A Work In Progress
The interest in psychedelics is growing each day, and, in time, most of them may become decriminalized. But where are psychedelics legal? With a handful of legal hallucinogens already available, interest continues to grow. So these alternative treatments for mental health issues may soon become common practice.
The 2025 Legal Landscape Update
The landscape of legally accessible psychedelics has changed significantly since this article was first written. Here’s where each major substance stands as of 2025.
Psilocybin moved from purely underground to partially regulated. Oregon launched the first regulated psilocybin service program in the U.S. in 2023 — licensed facilitators offer supervised psilocybin sessions for adults in approved service centers, with no diagnosis required. Colorado followed in 2024 with its Natural Medicine program. Australia approved psilocybin as a prescription treatment for treatment-resistant depression in 2023. More than a dozen U.S. cities have decriminalized personal possession. Psilocybin remains Schedule I federally — there is no federal prescription pathway, and the FDA’s review of Phase 3 trials won’t produce a decision before 2027–2028 at the earliest.
Ketamine remains the most broadly accessible legal psychedelic-adjacent treatment in the U.S. — available in all 50 states through licensed clinics. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and MDD with suicidal ideation; racemic IV ketamine is used off-label. Costs remain a barrier: IV ketamine typically $1,800–$3,000 per 6-session induction course, with limited insurance coverage. Telehealth ketamine companies offering at-home sublingual ketamine (Mindbloom, Nue Life) faced increased DEA and FDA scrutiny in 2024–2025, with some operational changes.
MDMA had a significant setback: the FDA rejected the MAPS PTSD application for MDMA-assisted therapy in August 2024, citing concerns about trial methodology and requesting additional Phase 3 data. MDMA remains Schedule I. The rejection was a major surprise to the psychedelic medicine field — MAPS is conducting additional trials while also dealing with organizational issues. MDMA-AT is not expected to receive FDA approval before 2028–2029 at the earliest, if then.
Ibogaine remains Schedule I in the U.S. but has gained significant attention for addiction treatment — particularly opioid use disorder. It is legal and used in Mexico and some European countries. Stanford researchers published a landmark 2023 study showing ibogaine dramatically reduced PTSD symptoms and depression in U.S. Special Forces veterans, which generated significant media coverage and congressional interest. Texas passed legislation in 2023 directing the state to study ibogaine for veteran PTSD; federal funding for trials has been proposed.
Ayahuasca is used legally under religious freedom protections by several federally recognized churches in the U.S. (União do Vegetal, Santo Daime). These protections apply to religious ceremony participants, not general public access. The number of ayahuasca retreats has proliferated internationally (Peru, Costa Rica, Netherlands, Portugal), and the unregulated retreat market carries the safety concerns documented in the companion article on ayahuasca dangers.
Frequently Asked Questions
What is the most accessible legal psychedelic in the U.S. right now?
Ketamine is by far the most accessible — available through licensed clinics in all 50 states, no diagnosis required at many providers, with Spravato (esketamine) FDA-approved specifically for treatment-resistant depression and insurance-coverable in some cases. For psilocybin specifically, Oregon and Colorado are the only states with regulated programs — costs typically $1,000–$3,500 per session. Clinical trial enrollment is another pathway for psilocybin and MDMA (for qualifying diagnoses). For most Americans outside Oregon and Colorado who want a psilocybin experience, either relocating temporarily to those states or enrolling in a trial are the only legal options.
Is ketamine actually a hallucinogen?
Technically, ketamine is classified as a dissociative anesthetic, not a classical hallucinogen. Classical hallucinogens (psilocybin, LSD, DMT, mescaline) work primarily through 5-HT2A serotonin receptor agonism. Ketamine works through NMDA glutamate receptor antagonism. The experiential effect at sub-anesthetic doses includes visual distortions, altered sense of time and space, and dissociation — which overlaps meaningfully with the “psychedelic experience” colloquially. The clinical community increasingly uses “psychedelic” broadly to include both serotonergic compounds and dissociatives like ketamine, given that both produce non-ordinary states of consciousness with therapeutic potential.
Are there any psychedelics that are completely legal federally in the U.S.?
Ketamine (Schedule III) is legal for medical use and legally prescribed. Spravato (esketamine) is FDA-approved. Kava, kratom, and certain legal psychoactive plants like mugwort, blue lotus, and Calea zacatechichi are legal federally, but they do not produce effects comparable to classic psychedelics. “Psychedelic Water” (a popular product) contains kava, damiana, and green tea extract — legal, but the experience is mild stimulant/anxiolytic, not psychedelic. Amanita muscaria mushrooms contain muscimol (not psilocybin) and are legal at the federal level, though their effects and safety profile differ significantly from psilocybin mushrooms. None of these are substitutes for classical psychedelics in clinical contexts.
What happened to MDMA therapy — is it still coming?
MDMA-assisted therapy for PTSD suffered a significant setback when the FDA rejected the MAPS application in August 2024. The FDA cited concerns about trial methodology, functional unblinding, and the need for additional Phase 3 data. MAPS is conducting additional trials; an FDA approval before 2028–2029 is considered unlikely. The rejection surprised many in the field, as earlier Phase 3 data was compelling. MDMA remains Schedule I. For PTSD patients, ketamine therapy is currently available as a legal option; Spravato specifically has FDA approval for MDD with acute suicidal ideation, which overlaps with many PTSD presentations.
